Jove
Visualize
Contact Us

Related Experiment Videos

[Psychic disorders]

P. Pollak1

  • 1Département de Neurologie, Centre Hospitalier Universitaire de Grenoble, INSERM U 318, Université Joseph Fourier de Grenoble, 38043 Grenoble Cedex 9.

Revue Neurologique
|April 12, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pollination- or Wound-Induced Kaempferol Accumulation in Petunia Stigmas Enhances Seed Production.

The Plant cell·1994
Same journal

Macrophage inclusions in patients undergoing antisense oligonucleotide therapy for ALS or SMA: A retrospective and transversal study.

Revue neurologique·2026
Same journal

Geographic disparities in MRI features of ischemic stroke and small vessel disease: A comparative study between French Guiana and mainland France. Findings from the BECATOUR multicenter registry.

Revue neurologique·2026
Same journal

Continuous subcutaneous perfusion of apomorphine in Parkinson's disease: Towards monotherapy?

Revue neurologique·2026
Same journal

Neuro-Whipple presenting as autoimmune encephalitis.

Revue neurologique·2026
Same journal

Multimodal assessment of minimally conscious state and cognitive motor dissociation in neurocritical care: A critical review.

Revue neurologique·2026
Same journal

Development of a new episodic memory assessment tool (NEM): Preliminary data and clinical perspectives.

Revue neurologique·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Psychiatric disorders in Parkinson's disease (PD) often stem from the disease itself and medications. Selective Serotonin Reuptake Inhibitors are recommended for depression, while psychosis management involves adjusting PD drugs and considering clozapine or quetiapine.

Area of Science:

  • Neurology
  • Psychiatry
  • Pharmacology

Background:

  • Parkinson's disease (PD) is a complex neuropsychiatric condition.
  • Psychic disorders, particularly depression and psychosis, are common in PD.
  • These disorders arise from neuropathological changes and antiparkinsonian medications.

Purpose of the Study:

  • To review the treatment strategies for depression and psychosis in Parkinson's disease.
  • To evaluate the efficacy and safety of pharmacological interventions for these conditions.

Main Methods:

  • Literature review of pharmacological treatments for depression and psychosis in PD.
  • Analysis of clinical studies on antidepressant and antipsychotic medications.
  • Evaluation of drug risk-benefit profiles in PD patients.

Related Experiment Videos

Main Results:

  • Selective Serotonin Reuptake Inhibitors are suggested as first-line treatment for depression in PD, requiring careful monitoring for potential parkinsonism worsening.
  • Psychosis treatment involves reducing antiparkinsonian drugs; clozapine is FDA-approved and effective, while quetiapine shows promise.
  • Olanzapine and risperidone may worsen parkinsonism and should be used cautiously.

Conclusions:

  • Effective management of depression and psychosis in PD requires tailored pharmacological approaches.
  • Careful selection and monitoring of medications are crucial to balance efficacy and side effects.
  • Further research is needed to clarify the role of other agents like anticholinesterases.